Cargando…
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in...
Autores principales: | Valanparambil, Rajesh M., Lai, Lilin, Johns, Margaret A., Davis-Gardner, Meredith, Linderman, Susanne L., McPherson, Tarrant Oliver, Chang, Andres, Akhtar, Akil, Gamarra, Estefany L. Bocangel, Matia, Hayley, McCook-Veal, Ashley A., Switchenko, Jeffrey, Nasti, Tahseen H., Green, Felicia, Saini, Manpreet, Wieland, Andreas, Pinsky, Benjamin A., Solis, Daniel, Dhodapkar, Madhav V., Carlisle, Jennifer, Ramalingam, Suresh, Ahmed, Rafi, Suthar, Mehul S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663480/ https://www.ncbi.nlm.nih.gov/pubmed/37990024 http://dx.doi.org/10.1038/s41541-023-00779-8 |
Ejemplares similares
-
BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
por: Ehmsen, Sidse, et al.
Publicado: (2023) -
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023) -
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023) -
XBB.1.5 an emerging threat: correspondence
por: Mohanty, Aroop, et al.
Publicado: (2023) -
Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)